VRAY is making big moves today after inking radiation therapy deal

Shares of Viewray Inc (VRAY) are trading 9% higher at a price of $3.995 at the time of this writing. While it's a dispirited day for the Health Care sector in general, the stock is surpassing it's peers.

Recent news:
- MD Anderson Cancer Center has selected ViewRay to expand their MR-guided radiation therapy program.
- ViewRay's MRI-guided radiation therapy has received approval in China.

Viewray Inc has been trading between a 52-week high of $8.25 and a 52-week low of $2.39. The stock has a market cap of $723 Million.

ViewRay, Inc., designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams.